Zheng Ming-Hua, Chen Yong-Ping
From the Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University (MHZ, YPC); and Institute of Hepatology, Wenzhou Medical University, Wenzhou, China (MHZ, YPC).
Medicine (Baltimore). 2015 Jan;94(1):e390. doi: 10.1097/MD.0000000000000390.
Combination treatment of pegylated interferon (PEG-IFN) plus ribavirin for renal transplant recipients (RTRs) with hepatitis C virus (HCV) infection remains controversial, as it has been associated with a high risk of rejection, resulting in graft loss and a reduction in patient survival.We present a special case of an elderly RTR who experienced treatment of HCV infection 8 years after renal transplant. There was no rejection episode during or after PEG-IFN treatment. The patient first received a 24-week therapy and a further 60-week course due to relapse. Cessation of both courses corresponded to an achieved end-of-treatment response. However, HCV infection reappeared shortly after cessation of the 60-week treatment period.This case highlights the safety of PEG-IFN therapy for elderly RTR and the potential importance of combination pretreatment for patients undergoing renal transplantation.
聚乙二醇干扰素（PEG-IFN）联合利巴韦林治疗丙型肝炎病毒（HCV）感染的肾移植受者（RTR）仍存在争议，因为它与高排斥风险相关，会导致移植肾丢失和患者生存率降低。我们报告了一例特殊的老年RTR病例，该患者在肾移植8年后接受了HCV感染治疗。PEG-IFN治疗期间及之后均未发生排斥反应。患者首先接受了24周的治疗，因复发又接受了60周的疗程。两个疗程结束均达到了治疗结束时的反应。然而，在60周治疗期结束后不久，HCV感染再次出现。该病例突出了PEG-IFN治疗对老年RTR的安全性以及对接受肾移植患者进行联合预处理的潜在重要性。
